Arkolith/Insider Trading/RDHL/Form 4

Raday Gilead

Chief Operating OfficerRedHill Biopharma Ltd. (RDHL) · full profile →Form 4 · filed Jul 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1K
Net Open-Market Flow
-$1K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 10, 2026Sell(S)14.1M$0.00$1K218.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 10, 2026Option exercise(M)28.1M—$0104.1M

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001178913-26-003473) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for RedHill Biopharma Ltd.

Build

Ask your agent about RDHL insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001178913-26-003473"
Ask your agent
Use Arkolith to summarize insider buying and selling at RedHill Biopharma Ltd.
over the last 90 days and cite the filings.